| Company Name: | Johnson & Johnson | | Ticker Symbol: | JNJ | | | WWW Address: | www.jnj.com | | CEO: | William C. Weldon | | No. of Employees: | 118,700 | | Common Issue Type: | CS | | Business Description: | A holding company, which is engaged in the research and development, manufacture and sale of a range of products in the health care field.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Major [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 62.31 |  0.37 | 60.97 | 62.48 | 61.82 | 62.62 | 61.72 | 16300134 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 171,919.5 | 2,759.1 | 0.55 | 4.57 | 1.80 | 13.6 | 3.1 | 62.74 - 46.25 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 62.31 | $ | | PE Ratio - LTM | 13.6 | |
| Market Capitalisation | 171,919.5 | mil |
| Latest Shares Outstanding | 2,759.1 | mil |
| Earnings pS (EPS) | 4.57 | $ |
| Dividend pS (DPS) | 1.80 | ¢ |
| Dividend Yield | 3.1 | % |
| Dividend Payout Ratio | 39 | % |
| Revenue per Employee | 537,043 | $ |
| Effective Tax Rate | 23.5 | % |
| Float | 2,754.7 | mil |
| Float as % of Shares Outstanding | 100.0 | % |
| Foreign Sales | 31,438 | mil |
| Domestic Sales | 32,309 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 32.80 | % |
| Research & Devlopment (R&D) as % of Revenue | 11.40 | % |
| Gross Profit Margin | 75.6 | % |
| EBITDA Margin | 31.5 | % |
| Pre-Tax Profit Margin | 27.5 | % |
| Assets Turnover | 0.7 | % |
| Return on Assets (ROA) | 14.0 | % |
| Return on Equity (ROE) | 25.4 | % |
| Return on Capital Invested (ROCI) | 21.8 | % |
| Current Ratio | 1.8 | |
| Leverage Ratio (Assets/Equity) | 1.8 | |
| Interest Cover | 36.6 | |
| Total Debt/Equity (Gearing Ratio) | 0.23 | |
| LT Debt/Total Capital | 14.0 | % |
| Working Capital pS | 5.93 | $ |
| Cash pS | 4.30 | $ |
| Book-Value pS | 18.26 | $ |
| Tangible Book-Value pS | 6.79 | $ |
| Cash Flow pS | 5.62 | $ |
| Free Cash Flow pS | 1.46 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 3.41 | |
| Price/Tangible Book Ratio | 9.18 | |
| Price/Cash Flow | 11.1 | |
| Price/Free Cash Flow | 42.7 | |
| P/E as % of Industry Group | 61.0 | % |
| P/E as % of Sector Segment | 81.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Dividend Declared Date | 10/25/2009 |
| Dividend Ex-Date | 11/19/2009 |
| Dividend Record Date | 11/23/2009 |
| Dividend Pay Date | 12/07/2009 |
| Dividend Amount | 490 |
| Type of Payment | Cash Payment |
| Dividend Rate | 1.96 |
| Current Dividend Yield | 3.1 |
| 5-Y Average Dividend Yield | 2.4 |
| Payout Ratio | 39.0 |
| 5-Y Average Payout Ratio | 40.0 |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 1.4 | 102 | 123,446 | 660,217 |
| 4 Weeks | 62.62 | 58.78 | 60.54 | 2.9 | 102 | 127,012 | 2,540,231 |
| 13 Weeks | 62.74 | 58.78 | 61.03 | 2.1 | 96 | 112,363 | 7,191,251 |
| 26 Weeks | 62.74 | 53.86 | 54.77 | 13.8 | 92 | 115,081 | 14,615,337 |
| 52 Weeks | 62.74 | 46.25 | 58.35 | 6.8 | 78 | 136,111 | 34,163,769 |
| YTD | 62.74 | 46.25 | - | 4.1 | 86 | 135,208 | 30,421,772 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 62.28 | 61.69 | 60.70 | 58.59 | 56.88 | 0.55 | 0.60 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 6.28 | 87.8 | 4.95 |
| Income | 9.14 | 87.5 | 7.77 |
| Dividend | 11.74 | 98.2 | 9.06 |
| Capital Spending | 7.69 | NA | -8.84 |
| R&D | 7.18 | NA | 0.87 |
| Normalized Inc. | 9.64 | NA | 6.28 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -6.6 | -5.3 | 4.3 |
| Earnings % | -1.7 | 1.1 | 22.4 |
| EPS % | 0.3 | 2.6 | 25.9 |
| EPS $ | 0.01 | 0.03 | 0.94 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 15.93 |
| Current Ratio | 1.6 |
| Quick Ratio (Acid Test) | 1.1 |
| Liquidity Ratio (Cash) | 0.61 |
| Receivables Turnover | 6.7 |
| Average Collection Period | 54 |
| Working Capital/Equity | 31.8 |
| Working Capital pS | 4.89 |
| Cash-Flow pS | 5.71 |
| Free Cash-Flow pS | 2.02 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 4.40 |
| Financial Leverage Ratio (Assets/Equity) | 2.0 |
| Debt Ratio | 49.9 |
| Total Debt/Equity (Gearing Ratio) | 0.28 |
| LT Debt/Equity | 0.19 |
| LT Debt/Capital Invested | 42.6 |
| LT Debt/Total Liabilities | 19.2 |
| Interest Cover | 39.9 |
| Interest/Capital Invested | 0.68 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 11.42 |
| Tobin's Q Ratio | 2.02 |
| Current P/E Ratio - LTM | 13.60 |
| Enterprise Value (EV)/EBITDA | 10.61 |
| Enterprise Value (EV)/Free Cash Flow | 39.90 |
| Dividend Yield | 3.1 |
| Price/Tangible Book Ratio - LTM | 9.18 |
| Price/Book Ratio - LTM | 3.41 |
| Price/Cash Flow Ratio | 11.1 |
| Price/Free Cash Flow Ratio - LTM | 42.7 |
| Price/Sales Ratio | 2.84 |
| P/E Ratio (1 month ago) - LTM | 13.2 |
| P/E Ratio (26 weeks ago) - LTM | 12.0 |
| P/E Ratio (52 weeks ago) - LTM | 13.2 |
| 5-Y High P/E Ratio | 22.6 |
| 5-Y Low P/E Ratio | 11.4 |
| 5-Y Average P/E Ratio | 17.8 |
| Current P/E Ratio as % of 5-Y Average P/E | 77 |
| P/E as % of Industry Group | 61.0 |
| P/E as % of Sector Segment | 81.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 13.5 |
| PER SHARE FIGURES |
| LT Debt pS | 2.94 |
| Current Liabilities pS | 7.54 |
| Tangible Book Value pS - LTM | 6.79 |
| Book Value pS - LTM | 18.26 |
| Capital Invested pS | 18.35 |
| Cash pS - LTM | 4.30 |
| Cash Flow pS - LTM | 5.62 |
| Free Cash Flow pS - LTM | 1.46 |
| Earnings pS (EPS) | 4.57 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 8.76 |
| Free Cash Flow Margin 5YEAR AVG | 3.57 |
| Net Profit Margin | 20.3 |
| Net Profit Margin - 5YEAR AVRG. | 19.4 |
| Equity Productivity | 1.50 |
| Return on Equity (ROE) | 30.5 |
| Return on Equity (ROE) - 5YEAR AVRG. | 27.5 |
| Capital Invested Productivity | 1.26 |
| Return on Capital Invested (ROCI) | 25.6 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 24.7 |
| Assets Productivity | 0.80 |
| Return on Assets (ROA) | 15.2 |
| Return on Assets (ROA) - 5YEAR AVRG. | 15.4 |
| Gross Profit Margin | 75.6 |
| Gross Profit Margin - 5YEAR AVRG. | 75.8 |
| EBITDA Margin - LTM | 31.5 |
| EBIT Margin - LTM | 28.3 |
| Pre-Tax Profit Margin | 26.6 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 25.8 |
| Effective Tax Rate | 23.5 |
| Effective Tax Rate - 5YEAR AVRG. | 25.1 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 172 |
| Revenue per Employee | 537,043 |
| Net Income per Employee | 109,090 |
| Average Collection Period | 55 |
| Receivables Turnover | 6.7 |
| Day's Inventory Turnover Ratio | 117 |
| Inventory Turnover | 3.1 |
| Inventory/Sales | 7.9 |
| Accounts Payble/Sales | 11.77 |
| Assets/Revenue | 1.25 |
| Net Working Capital Turnover | 4.71 |
| Fixed Assets Turnover | 1.26 |
| Total Assets Turnover | 0.8 |
| Revenue per $ Cash | 5.92 |
| Revenue per $ Plant | 4.44 |
| Revenue per $ Common Equity | 1.50 |
| Revenue per $ Capital Invested | 1.26 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 33.7 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 33.4 |
| Research & Devlopment (R&D) as % of Revenue | 11.9 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 11.9 |
|
|  
| | |  |  | |
| |